According to guidelines, at what point should a patient with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD) be referred for lung transplantation?

Lung Transplant Referral Criteria for ILD and COPD

For COPD patients, refer for lung transplantation when they have progressive disease despite optimal medical management with a BODE index of 5-6, PCO₂ >50 mmHg (6.6 kPa) and/or PaO₂ <60 mmHg (8 kPa), and FEV₁ <25% predicted, while for ILD patients, refer when there is evidence of progressive pulmonary fibrosis with declining lung function despite antifibrotic therapy. 1

COPD Referral Criteria

Refer COPD patients for transplant evaluation when they meet the following criteria: 1

• Progressive disease despite maximal medical therapy (including bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation)
• Not a candidate for endoscopic or surgical lung volume reduction procedures
• BODE index of 5-6 (Body mass index, airflow Obstruction, Dyspnea, Exercise capacity)
• PCO₂ >50 mmHg (6.6 kPa) and/or PaO₂ <60 mmHg (8 kPa)
• FEV₁ <25% predicted

COPD Listing Criteria (Higher Priority)

List COPD patients for transplantation when they meet one or more of the following: 1

• BODE index >7
• FEV₁ <15-20% predicted
• Three or more severe exacerbations during the preceding year
• One severe exacerbation with acute hypercapnic respiratory failure
• Moderate to severe pulmonary hypertension

ILD/IPF Referral and Listing Criteria

For patients with idiopathic pulmonary fibrosis and other progressive fibrotic ILDs, the approach differs from COPD: 1, 2

Timing of Referral for ILD

Refer ILD patients early when they demonstrate: 1, 3

• Progressive disease despite antifibrotic therapy (nintedanib or pirfenidone)
• Patients at increased risk of mortality should be referred at diagnosis to allow adequate time for evaluation 1

Criteria for Progressive Pulmonary Fibrosis (PPF)

PPF is defined as at least two of the following three criteria occurring within the past year: 1

1. Worsening respiratory symptoms
2. Physiological evidence of disease progression:
   • Absolute decline in FVC >5% predicted within 1 year, OR
   • Absolute decline in DLCO (corrected for Hb) >10% predicted within 1 year
3. Radiological evidence of disease progression on HRCT

Additional High-Risk ILD Features

Consider earlier referral when patients demonstrate: 4, 3

• Relative decline of FVC ≥10% in 6 months (associated with 1.72-fold increased mortality risk) 4
• 6-minute walk distance <250 meters (associated with 2.77-fold increased mortality risk) 4
• Desaturation below 88% on 6-minute walk test 3
• Development or worsening of pulmonary hypertension 1, 3

Key Clinical Pitfalls

Common mistakes to avoid: 1, 2, 5

• Delaying referral until patients are too sick for transplantation—refer early when progression is documented, not when respiratory failure is imminent 2
• Waiting for absolute contraindications to develop—comorbidities that accumulate over time may render patients ineligible 2
• Failing to recognize that median survival post-transplant for COPD is only 6.0 years, so timing must balance waitlist mortality against post-transplant outcomes 5
• Not accounting for geographic variation in wait times—organ availability varies significantly by region and should influence listing decisions 6

Monitoring Frequency

Once referred or listed, monitor patients closely: 1

• Pulmonary function testing and 6-minute walk test every 4-6 months or sooner if clinically indicated 1
• Annual HRCT if there is clinical suspicion of worsening or risk of lung cancer 1
• HRCT if concern for acute exacerbation 1

Disease-Specific Considerations

The GOLD guidelines provide specific COPD criteria, while the ATS/ERS/JRS/ALAT guidelines address ILD/IPF with emphasis on progressive phenotypes 1. The key distinction is that COPD referral relies heavily on objective measures (BODE index, gas exchange, spirometry), whereas ILD referral emphasizes the trajectory of decline (rate of FVC loss, functional deterioration) rather than absolute values alone 1, 4.